Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Investing.com - Morgan Stanley (NYSE: MS) has reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Trial reported MASH and fibrosis improvements with dapagliflozin. ... 29% for semaglutide, and 20% for resmetirom," the editorialists wrote.

GLP-1 receptor agonist semaglutide significantly outperformed placebo in an ongoing phase 3 trial, showing reductions in steatohepatitis and liver fibrosis, in addition to cardiometabolic benefits.